Roquefort Therapeutics is headquartered in London and is publicly traded on the London Stock Exchange (LSE:ROQ) and the OTC Markets in the US (OTCQB: ROQAF)
Roquefort Therapeutics is a material biotech company focused on developing first in class, next generation medicines in the high value and high growth oncology market prior to partnering or selling to big pharma.
The Company has partnered with leading academic cancer research centres which complements our own world-class in-house expertise and laboratory infrastructure.
We are well positioned with five pre-clinical drug development programs, and have the foundation and team to deliver the key R&D and commercial milestones that will drive shareholder value.
